Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab

Yangyang Duan, Tao Sun, Zhanhong Chen, Quchang Ouyang, Kai Li, Min Yan, Zheng Lv, Zhaohui Li, Man Li, Luo Xu, Yuyang Dong, Mingxi Jing, Yan Wang, Xiangyu Guo, Junnan Xu, Xiaorui Li, Cui Jiang, Er‐Bo Ying, Lei Jiang, Hui Cao, Yufeng Jia, Jie Wu, Huan Li, Liang Zhang, Yujun Jiang, Zhichao Gao, Fangyuan DongFrontiers in Oncology 2025 · DOI

This study, published in Frontiers in Oncology, provides the first large-scale, real-world evidence for the efficacy of inetetamab—a novel, Chinese-developed anti-HER2 monoclonal antibody—in patients with metastatic breast cancer who have already failed standard trastuzumab therapy.

TL;DR

In a multicenter study of 500 patients, inetetamab-based therapy demonstrated a median progression-free survival (PFS) of 8.0 months in HER2-positive metastatic breast cancer patients previously treated with trastuzumab. The most effective regimen was a "triple combination" of inetetamab, tyrosine kinase inhibitors (TKIs), and chemotherapy, which extended PFS to 9.0 months with a manageable safety profile.

What Problem Does This Paper Address?

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is highly aggressive. While the drug trastuzumab (Herceptin) revolutionized treatment, most patients eventually develop resistance. Subsequent options like Antibody-Drug Conjugates (ADCs) and various TKIs exist, but they are often prohibitively expensive or have limited availability in certain regions.

Inetetamab was developed as a more economical and effective anti-HER2 alternative. However, until now, data on its performance specifically in "trastuzumab-exposed" populations was limited to small, single-center studies. This paper addresses the need for robust, large-scale clinical evidence to determine if inetetamab is a viable "next step" for patients who have exhausted standard first-line treatments.

Methods

The researchers conducted a multicenter retrospective study collecting data from 500 patients across several Chinese hospitals between July 2020 and October 2023.

  • Primary Endpoint: Progression-free survival (PFS).
  • Secondary Endpoints: Objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).
  • Statistical Analysis: The team used Kaplan-Meier curves to estimate survival and Cox proportional hazards regression to identify independent risk factors (like Ki67 index and metastatic sites) that influenced treatment outcomes.

Datasets

The "dataset" consists of clinicopathological records from 500 patients with HER2-positive metastatic breast cancer (MBC). All patients had a history of trastuzumab treatment, and many had also failed prior TKIs or ADCs. This represents one of the largest real-world cohorts for this specific drug to date.

Key Insights and Ideas

  • The "Triple Combo" Advantage: The study found that combining inetetamab with both a TKI and chemotherapy yielded the best results (9.0 months PFS). This suggests a synergistic effect where the antibody and the small-molecule inhibitor attack the HER2 pathway from different angles (extracellular vs. intracellular).
  • Economic Viability: A recurring theme in the paper is the "financial toxicity" of newer ADCs like T-DXd. The authors position inetetamab as a crucial, more affordable option that maintains high efficacy, particularly in resource-constrained settings.
  • Predictive Biomarkers: The study identified the Ki67 index (a marker of cell proliferation) and the presence of distant lymph node metastasis as independent predictors of PFS. Patients with lower Ki67 levels tended to respond better to the therapy.
  • Line-Agnostic Efficacy: Surprisingly, inetetamab showed sustained activity even in heavily pre-treated patients (5th-line therapy and beyond), maintaining a median PFS of 6.0 months in that subgroup.

Key Results

  • Overall Efficacy: Across the entire cohort, the median PFS was 8.0 months, with an ORR of 28.6% and a DCR of 89.2%.
  • Subgroup Performance: The inetetamab + TKI + chemo group achieved the highest ORR at 29.3% and a DCR of 92.8%.
  • Safety Profile: The treatment was generally well-tolerated. The most common adverse events were neutropenia (36.4%) and leukopenia (31.4%).
  • Cardiac Safety: Notably, no specific cardiotoxicity (like a significant drop in LVEF) was observed, which is a major concern with many HER2-targeted therapies.

Limitations and Future Work

As a retrospective study, the work is subject to inherent selection biases and relies on the accuracy of existing medical records. Furthermore, the study focused primarily on PFS; Overall Survival (OS) data was not yet mature enough for a comprehensive analysis.

The authors conclude that while these real-world results are promising, prospective randomized controlled trials are necessary to definitively compare inetetamab-based regimens against other emerging second- and third-line standards like T-DXd. Future research should also focus on refining biomarker-guided patient stratification to identify who will benefit most from the "triple combination" approach.

Summary updated

Abstract

Inetetamab was promising in HER2-positive MBC patients who had prior exposure to trastuzumab, offering a new option for patients with a prior failure of trastuzumab.
BibTeX
@inproceedings{duan2025real,
  author = {Yangyang Duan and Tao Sun and Zhanhong Chen and Quchang Ouyang and Kai Li and Min Yan and Zheng Lv and Zhaohui Li and Man Li and Luo Xu and Yuyang Dong and Mingxi Jing and Yan Wang and Xiangyu Guo and Junnan Xu and Xiaorui Li and Cui Jiang and Er‐Bo Ying and Lei Jiang and Hui Cao and Yufeng Jia and Jie Wu and Huan Li and Liang Zhang and Yujun Jiang and Zhichao Gao and Fangyuan Dong},
  title = {{Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2025.1496371},
}
Figure